Skip to Content

MYLAN 2045 MYLAN 2045 (Tacrolimus 0.5 mg)

Pill with imprint MYLAN 2045 MYLAN 2045 is Orange / Gray, Capsule-shape and has been identified as Tacrolimus 0.5 mg. It is supplied by Mylan Pharmaceuticals Inc..

Tacrolimus is used in the treatment of organ transplant, rejection prophylaxis; nephrotic syndrome; organ transplant, rejection reversal; graft-versus-host disease; crohn's disease and belongs to the drug class calcineurin inhibitors. Risk cannot be ruled out during pregnancy. Tacrolimus 0.5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for MYLAN 2045 MYLAN 2045

Tacrolimus

Imprint:
MYLAN 2045 MYLAN 2045
Strength:
0.5 mg
Color:
Orange / Gray
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Calcineurin inhibitors
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Mylan Pharmaceuticals Inc.
Inactive Ingredients:
lactose anhydrous
ferrosoferric oxide
silicon dioxide
croscarmellose sodium
gelatin
hypromelloses
lactose monohydrate
magnesium stearate
sodium lauryl sulfate
titanium dioxide
ferric oxide yellow
D&C Red No. 28
D&C Yellow No. 10
FD&C Red No. 40
FD&C Blue No. 1
FD&C Blue No. 2
propylene glycol
shellac
Note: Inactive ingredients may vary.

Other Labelers / Repackagers:

NDC CodeLabeler / Repackager
51079-0817 UDL Laboratories Inc.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide